741 related articles for article (PubMed ID: 25595145)
21. The EMIF-AD PreclinAD study: study design and baseline cohort overview.
Konijnenberg E; Carter SF; Ten Kate M; den Braber A; Tomassen J; Amadi C; Wesselman L; Nguyen HT; van de Kreeke JA; Yaqub M; Demuru M; Mulder SD; Hillebrand A; Bouwman FH; Teunissen CE; Serné EH; Moll AC; Verbraak FD; Hinz R; Pendleton N; Lammertsma AA; van Berckel BNM; Barkhof F; Boomsma DI; Scheltens P; Herholz K; Visser PJ
Alzheimers Res Ther; 2018 Aug; 10(1):75. PubMed ID: 30075734
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment.
Park JH; Seo SW; Kim C; Kim GH; Noh HJ; Kim ST; Kwak KC; Yoon U; Lee JM; Lee JW; Shin JS; Kim CH; Noh Y; Cho H; Kim HJ; Yoon CW; Oh SJ; Kim JS; Choe YS; Lee KH; Lee JH; Ewers M; Weiner MW; Werring DJ; Na DL
Ann Neurol; 2013 May; 73(5):584-93. PubMed ID: 23495089
[TBL] [Abstract][Full Text] [Related]
23. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
[TBL] [Abstract][Full Text] [Related]
24. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases.
Murray AD; Staff RT; McNeil CJ; Salarirad S; Ahearn TS; Mustafa N; Whalley LJ
Brain; 2011 Dec; 134(Pt 12):3687-96. PubMed ID: 22102649
[TBL] [Abstract][Full Text] [Related]
25. Association of lifetime cognitive engagement and low β-amyloid deposition.
Landau SM; Marks SM; Mormino EC; Rabinovici GD; Oh H; O'Neil JP; Wilson RS; Jagust WJ
Arch Neurol; 2012 May; 69(5):623-29. PubMed ID: 22271235
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
27. Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline.
Ayton S; Fazlollahi A; Bourgeat P; Raniga P; Ng A; Lim YY; Diouf I; Farquharson S; Fripp J; Ames D; Doecke J; Desmond P; Ordidge R; Masters CL; Rowe CC; Maruff P; Villemagne VL; ; Salvado O; Bush AI
Brain; 2017 Aug; 140(8):2112-2119. PubMed ID: 28899019
[TBL] [Abstract][Full Text] [Related]
28. Low amyloid-β deposition correlates with high education in cognitively normal older adults: a pilot study.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T
Int J Geriatr Psychiatry; 2015 Sep; 30(9):919-26. PubMed ID: 25425062
[TBL] [Abstract][Full Text] [Related]
29. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
30. Effects of amyloid and small vessel disease on white matter network disruption.
Kim HJ; Im K; Kwon H; Lee JM; Ye BS; Kim YJ; Cho H; Choe YS; Lee KH; Kim ST; Kim JS; Lee JH; Na DL; Seo SW
J Alzheimers Dis; 2015; 44(3):963-75. PubMed ID: 25374100
[TBL] [Abstract][Full Text] [Related]
31. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.
Villemagne VL; Pike KE; Darby D; Maruff P; Savage G; Ng S; Ackermann U; Cowie TF; Currie J; Chan SG; Jones G; Tochon-Danguy H; O'Keefe G; Masters CL; Rowe CC
Neuropsychologia; 2008; 46(6):1688-97. PubMed ID: 18343463
[TBL] [Abstract][Full Text] [Related]
32. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease.
Yassi N; Hilal S; Xia Y; Lim YY; Watson R; Kuijf H; Fowler C; Yates P; Maruff P; Martins R; Ames D; Chen C; Rowe CC; Villemagne VL; Salvado O; Desmond PM; Masters CL
J Alzheimers Dis; 2020; 73(3):897-907. PubMed ID: 31884485
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
[TBL] [Abstract][Full Text] [Related]
34. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia.
Ye BS; Seo SW; Kim JH; Kim GH; Cho H; Noh Y; Kim HJ; Yoon CW; Woo SY; Kim SH; Park HK; Kim ST; Choe YS; Lee KH; Kim JS; Oh SJ; Kim C; Weiner M; Lee JH; Na DL
Neurology; 2015 Nov; 85(19):1687-93. PubMed ID: 26468407
[TBL] [Abstract][Full Text] [Related]
35. Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly.
Vogel JW; Varga Doležalová M; La Joie R; Marks SM; Schwimmer HD; Landau SM; Jagust WJ
Neurology; 2017 Nov; 89(19):2002-2009. PubMed ID: 28986416
[TBL] [Abstract][Full Text] [Related]
36. Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory.
Han JW; Maillard P; Harvey D; Fletcher E; Martinez O; Johnson DK; Olichney JM; Farias ST; Villeneuve S; Jagust W; Mungas D; DeCarli C
Neurology; 2020 Nov; 95(19):e2622-e2634. PubMed ID: 32732300
[TBL] [Abstract][Full Text] [Related]
37. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.
Ellis KA; Lim YY; Harrington K; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P;
J Alzheimers Dis; 2013; 34(4):861-71. PubMed ID: 23302660
[TBL] [Abstract][Full Text] [Related]
38. Influence of Amyloid-β on Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study.
Liu W; Wong A; Au L; Yang J; Wang Z; Leung EY; Chen S; Ho CL; Mok VC
Stroke; 2015 Nov; 46(11):3074-80. PubMed ID: 26382174
[TBL] [Abstract][Full Text] [Related]
39. Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults.
Snitz BE; Weissfeld LA; Cohen AD; Lopez OL; Nebes RD; Aizenstein HJ; McDade E; Price JC; Mathis CA; Klunk WE
Am J Geriatr Psychiatry; 2015 Sep; 23(9):985-93. PubMed ID: 25746485
[TBL] [Abstract][Full Text] [Related]
40. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Roberts RO; Lowe VJ; Kantarci K; Senjem ML; Gunter JL; Boeve BF; Petersen RC; Jack CR
Ann Neurol; 2012 Nov; 72(5):730-8. PubMed ID: 23280791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
